CDTX Cidara Therapeutics

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.

Presentation details are summarized below:

Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study.

Presenter: Voon Ong, Ph.D.

Session: Late Breakers: Novel and Outstanding Discoveries

Session Date and Time: Thursday, October 23, 2025, 2:00-3:30 pm CET

About Cidara Therapeutics

Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:

Brian Ritchie

LifeSci Advisors

(212) 915-2578

MEDIA CONTACT:

Michael Fitzhugh

LifeSci Communications

(628) 234-3889



EN
10/10/2025

Underlying

CDTXCidara Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. Presentation details are summarized below: Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Dru...

10h / 23m 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation...

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescent...

October 9, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufact...

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Departm...

October 2, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCH...

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeu...

September 25, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan fo...

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidar...

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch